These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 36550562

  • 1. Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design.
    Nickerson PW, Böhmig GA, Chadban S, Kumar D, Mannon RB, van Gelder T, Lee JC, Adler S, Chong E, Djamali A.
    Trials; 2022 Dec 22; 23(1):1042. PubMed ID: 36550562
    [Abstract] [Full Text] [Related]

  • 2. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.
    Eskandary F, Dürr M, Budde K, Doberer K, Reindl-Schwaighofer R, Waiser J, Wahrmann M, Regele H, Spittler A, Lachmann N, Firbas C, Mühlbacher J, Bond G, Halloran PF, Chong E, Jilma B, Böhmig GA.
    Trials; 2019 Jan 11; 20(1):37. PubMed ID: 30635033
    [Abstract] [Full Text] [Related]

  • 3. A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection.
    Doberer K, Duerr M, Halloran PF, Eskandary F, Budde K, Regele H, Reeve J, Borski A, Kozakowski N, Reindl-Schwaighofer R, Waiser J, Lachmann N, Schranz S, Firbas C, Mühlbacher J, Gelbenegger G, Perkmann T, Wahrmann M, Kainz A, Ristl R, Halleck F, Bond G, Chong E, Jilma B, Böhmig GA.
    J Am Soc Nephrol; 2021 Mar 11; 32(3):708-722. PubMed ID: 33443079
    [Abstract] [Full Text] [Related]

  • 4. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
    Eskandary F, Bond G, Schwaiger E, Kikic Z, Winzer C, Wahrmann M, Marinova L, Haslacher H, Regele H, Oberbauer R, Böhmig GA.
    Trials; 2014 Apr 03; 15():107. PubMed ID: 24708575
    [Abstract] [Full Text] [Related]

  • 5. Chronic Active Antibody-mediated Rejection: Opportunity to Determine the Role of Interleukin-6 Blockade.
    Berger M, Baliker M, Van Gelder T, Böhmig GA, Mannon RB, Kumar D, Chadban S, Nickerson P, Lee LA, Djamali A.
    Transplantation; 2024 May 01; 108(5):1109-1114. PubMed ID: 37941113
    [Abstract] [Full Text] [Related]

  • 6. Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study).
    Streichart L, Felldin M, Ekberg J, Mjörnstedt L, Lindnér P, Lennerling A, Bröcker V, Mölne J, Holgersson J, Daenen K, Wennberg L, Lorant T, Baid-Agrawal S.
    Trials; 2024 Mar 22; 25(1):213. PubMed ID: 38519988
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of Clazakizumab (Anti-Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts.
    Jordan SC, Ammerman N, Choi J, Huang E, Najjar R, Peng A, Sethi S, Sandhu R, Atienza J, Toyoda M, Ge S, Lim K, Gillespie M, Zhang X, Haas M, Vo A.
    Kidney Int Rep; 2022 Apr 22; 7(4):720-731. PubMed ID: 35497778
    [Abstract] [Full Text] [Related]

  • 8. A Banff-based histologic chronicity index is associated with graft loss in patients with a kidney transplant and antibody-mediated rejection.
    Haas M, Mirocha J, Huang E, Najjar R, Peng A, Sethi S, Vo A, Anglicheau D, Jordan SC, Rabant M.
    Kidney Int; 2023 Jan 22; 103(1):187-195. PubMed ID: 36332728
    [Abstract] [Full Text] [Related]

  • 9. Clazakizumab for desensitization in highly sensitized patients awaiting transplantation.
    Vo AA, Huang E, Ammerman N, Toyoda M, Ge S, Haas M, Zhang X, Peng A, Najjar R, Williamson S, Myers C, Sethi S, Lim K, Choi J, Gillespie M, Tang J, Jordan SC.
    Am J Transplant; 2022 Apr 22; 22(4):1133-1144. PubMed ID: 34910841
    [Abstract] [Full Text] [Related]

  • 10. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
    Moreso F, Crespo M, Ruiz JC, Torres A, Gutierrez-Dalmau A, Osuna A, Perelló M, Pascual J, Torres IB, Redondo-Pachón D, Rodrigo E, Lopez-Hoyos M, Seron D.
    Am J Transplant; 2018 Apr 22; 18(4):927-935. PubMed ID: 28949089
    [Abstract] [Full Text] [Related]

  • 11. Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial.
    Mayer KA, Budde K, Halloran PF, Doberer K, Rostaing L, Eskandary F, Christamentl A, Wahrmann M, Regele H, Schranz S, Ely S, Firbas C, Schörgenhofer C, Kainz A, Loupy A, Härtle S, Boxhammer R, Jilma B, Böhmig GA.
    Trials; 2022 Apr 08; 23(1):270. PubMed ID: 35395951
    [Abstract] [Full Text] [Related]

  • 12. New concepts in chronic antibody-mediated kidney allograft rejection: prevention and treatment.
    Mayer KA, Doberer K, Eskandary F, Halloran PF, Böhmig GA.
    Curr Opin Organ Transplant; 2021 Feb 01; 26(1):97-105. PubMed ID: 33315763
    [Abstract] [Full Text] [Related]

  • 13. Plasma-Derived C1 Esterase Inhibitor for Acute Antibody-Mediated Rejection Following Kidney Transplantation: Results of a Randomized Double-Blind Placebo-Controlled Pilot Study.
    Montgomery RA, Orandi BJ, Racusen L, Jackson AM, Garonzik-Wang JM, Shah T, Woodle ES, Sommerer C, Fitts D, Rockich K, Zhang P, Uknis ME.
    Am J Transplant; 2016 Dec 01; 16(12):3468-3478. PubMed ID: 27184779
    [Abstract] [Full Text] [Related]

  • 14. Change in Estimated GFR and Risk of Allograft Failure in Patients Diagnosed With Late Active Antibody-mediated Rejection Following Kidney Transplantation.
    Irish W, Nickerson P, Astor BC, Chong E, Wiebe C, Moreso F, Seron D, Crespo M, Gache L, Djamali A.
    Transplantation; 2021 Mar 01; 105(3):648-659. PubMed ID: 33617203
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies.
    Glotz D, Russ G, Rostaing L, Legendre C, Tufveson G, Chadban S, Grinyó J, Mamode N, Rigotti P, Couzi L, Büchler M, Sandrini S, Dain B, Garfield M, Ogawa M, Richard T, Marks WH, C10-002 Study Group.
    Am J Transplant; 2019 Oct 01; 19(10):2865-2875. PubMed ID: 31012541
    [Abstract] [Full Text] [Related]

  • 16. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.
    Eskandary F, Regele H, Baumann L, Bond G, Kozakowski N, Wahrmann M, Hidalgo LG, Haslacher H, Kaltenecker CC, Aretin MB, Oberbauer R, Posch M, Staudenherz A, Handisurya A, Reeve J, Halloran PF, Böhmig GA.
    J Am Soc Nephrol; 2018 Feb 01; 29(2):591-605. PubMed ID: 29242250
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial.
    Marks WH, Mamode N, Montgomery RA, Stegall MD, Ratner LE, Cornell LD, Rowshani AT, Colvin RB, Dain B, Boice JA, Glotz D, C10-001 Study Group.
    Am J Transplant; 2019 Oct 01; 19(10):2876-2888. PubMed ID: 30887675
    [Abstract] [Full Text] [Related]

  • 18. Treatment of Antibody-Mediated Rejection After Kidney Transplantation: Immunological Effects, Clinical Response, and Histological Findings.
    de Sousa MV, Gonçalez AC, de Lima Zollner R, Mazzali M.
    Ann Transplant; 2020 Nov 17; 25():e925488. PubMed ID: 33199675
    [Abstract] [Full Text] [Related]

  • 19. A Randomized Trial Comparing Imlifidase to Plasmapheresis in Kidney Transplant Recipients With Antibody-Mediated Rejection.
    Halleck F, Böhmig GA, Couzi L, Rostaing L, Einecke G, Lefaucheur C, Legendre C, Montgomery R, Hughes P, Chandraker A, Wyburn K, Halloran P, Maldonado AQ, Sjöholm K, Runström A, Lefèvre P, Tollemar J, Jordan S.
    Clin Transplant; 2024 Jul 17; 38(7):e15383. PubMed ID: 39023092
    [Abstract] [Full Text] [Related]

  • 20. Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Renal Allograft Rejection: Accumulation of Antibody-neutralized Interleukin-6 Without Signs of Proinflammatory Rebound Phenomena.
    Borski A, Eskandary F, Haindl S, Doberer K, Mühlbacher J, Mayer KA, Budde K, Halloran PF, Chong E, Jilma B, Böhmig GA, Wahrmann M.
    Transplantation; 2023 Feb 01; 107(2):495-503. PubMed ID: 35969004
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.